ESMO 2022 | IMMUNED: adjuvant nivolumab and ipilimumab increases OS in stage IV melanoma

Dirk Schadendorf, MD, University Hospital Essen, Essen, Germany, discusses the results of the Phase II IMMUNED trial (NCT02523313), a randomized, double-blind multi-center trial which evaluated adjuvant nivolumab alone or in combination with ipilimumab versus placebo in stage IV melanoma with no evidence of disease. Nivolumab and nivolumab with ipilimumab continued to demonstrate improved relapse-free survival in stage IV patients at high risk of recurrence. Overall survival was markedly improved for patients receiving nivolumab and ipilimumab compared with placebo. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.